# Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Source: https://onco.cc/trials/nct05417789/  
OnCo record `nct05417789` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Emactuzumab in tenosynovial giant cell tumour, active and no longer recruiting.

## Summary

Study of Emactuzumab for Tenosynovial Giant Cell Tumour (TGCT) is a phase 3 interventional study registered as NCT05417789, led by SynOx Therapeutics, and active but no longer recruiting on the registry. Official title: A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour. Planned enrolment is 128 participants (estimated). The study started in 2024-10-09 and primary completion is expected in 2025-12-23. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: TANGENT
- Tags: ctgov-ingest
- Registry id: NCT05417789
- Phase: 3
- Setting: A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour
- Sponsor: SynOx Therapeutics
- Enrolled: 128

## Sources

- ClinicalTrials.gov NCT05417789: https://clinicaltrials.gov/study/NCT05417789

## Connected records

- cancers: [Tenosynovial giant cell tumour (TGCT)](https://onco.cc/cancers/tenosynovial-giant-cell-tumour/)
- drugs: [Emactuzumab](https://onco.cc/drugs/emactuzumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05417789.json